Pessaries in multiple pregnancy as a prevention of preterm birth: the ProTwin Trial by Hegeman, A.M. et al.
BioMed CentralBMC Pregnancy and Childbirth
ssOpen AcceStudy protocol
Pessaries in multiple pregnancy as a prevention of preterm birth: 
the ProTwin Trial
Maud A Hegeman*1, Dick J Bekedam1, Kitty WM Bloemenkamp2, 
Anneke Kwee3, Dimitri NM Papatsonis4, Joris AM van der Post5, 
Arianne C Lim5, Hubertina CJ Scheepers6, Christine Willekes6, 
Johannes J Duvekot7, Marc Spaanderman8, Martina Porath9, Jim van Eyck10, 
Monique C Haak11, Marielle G van Pampus12, Hein W Bruinse3 and Ben 
Willem J Mol5
Address: 1Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis Amsterdam, the Netherlands, 2Department of Obstetrics and 
Gynaecology, Leiden University Medical Center, the Netherlands, 3Department of Obstetrics and Gynaecology, University Medical Centre, Utrecht, 
the Netherlands, 4Department of Obstetrics and Gynaecology, AMPHIA hospital, Breda, the Netherlands, 5Department of Obstetrics and 
Gynaecology, Academic Medical Centre Amsterdam, the Netherlands, 6Department of Obstetrics and Gynaecology, Academic Hospital Maastricht, 
the Netherlands, 7Department of Obstetrics and Gynaecology, Erasmus Medical Center Rotterdam, the Netherlands, 8Department of Obstetrics 
and Gynaecology, University Medical Center St Radboud Nijmegen, the Netherlands, 9Department of Obstetrics and Gynaecology, Máxima 
Medical Center Veldhoven, the Netherlands, 10Department of Obstetrics and Gynaecology, Isala Hospital, Zwolle, the Netherlands, 11Department 
of Obstetrics and Gynaecology, VU Medical Center Amsterdam, the Netherlands and 12Department of Obstetrics and Gynaecology, University 
Medical Center Groningen, the Netherlands
Email: Maud A Hegeman* - protwintrial@gmail.com; Dick J Bekedam - d.j.bekedam@olvg.nl; 
Kitty WM Bloemenkamp - k.w.m.bloemenkamp@lumc.nl; Anneke Kwee - a.kwee@umcutrecht.nl; Dimitri NM Papatsonis - hoog.pap@wxs.nl; 
Joris AM van der Post - j.a.vanderpost@amc.uva.nl; Arianne C Lim - a.c.lim@amc.uva.nl; Hubertina CJ Scheepers - hcj.scheepers@mumc.nl; 
Christine Willekes - cwi@sgyn.azm.nl; Johannes J Duvekot - j.j.duvekot@erasmusmc.nl; 
Marc Spaanderman - M.Spaanderman@obgyn.umcn.nl; Martina Porath - m.porath@mmc.nl; Jim van Eyck - jvaneyck@wxs.nl; 
Monique C Haak - mc.haak@vumc.nl; Marielle G van Pampus - m.van.pampus@og.umcg.nl; Hein W Bruinse - H.W.Bruinse@umcutrecht.nl; 
Ben Willem J Mol - b.w.mol@amc.uva.nl
* Corresponding author    
Abstract
Background: Multiple pregnancies are at high risk for preterm birth, and therefore an important
cause of infant mortality and morbidity. A pessary is a simple and potentially effective measure for
the prevention of preterm birth. Small studies have indicated its effectiveness, but large studies with
sufficient power on the subject are lacking. Despite this lack of evidence, the treatment is at present
applied by some gynaecologists in The Netherlands.
Methods/Design: We aim to investigate the hypothesis that prophylactic use of a cervical pessary
will be effective in the prevention of preterm delivery and the neonatal mortality and morbidity
resulting from preterm delivery in multiple pregnancy. We will evaluate the costs and effects of this
intervention. At study entry, cervical length will be measured. Eligible women will be randomly
allocated to receive either a cervical pessary or no intervention. The cervical pessary will be placed
in situ at 16 to 20 weeks, and will stay in situ up to 36 weeks gestation or until delivery, whatever
comes first.
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BMC Pregnancy and Childbirth 2009, 9:44 http://www.biomedcentral.com/1471-2393/9/44The primary outcome is composite bad neonatal condition (perinatal death or severe morbidity).
Secondary outcome measures are time to delivery, preterm birth rate before 32 and 37 weeks,
days of admission in neonatal intensive care unit, maternal morbidity, maternal admission days for
preterm labour and costs. We need to include 660 women to indicate a reduction in bad neonatal
outcome from 7.2% without to 3.9% with a cervical pessary, using a two-sided test with an alpha
of 0.05 and a power of 0.80.
Discussion: This trial will provide evidence on whether a cervical pessary will decrease the
incidence of early preterm birth and its concomitant bad neonatal outcome in multiple pregnancies.
Trial registration: Current Controlled Trials: NTR 1858
Background
Twin pregnancies are at high risk for preterm birth. In The
Netherlands 15% of the women with a multiple preg-
nancy deliver before 34 weeks of gestation[1]. About 1 in
60 pregnancies is a twin pregnancy, and about 30% of the
preterm born children admitted in a neonatal care
(NICU) are from twin pregnancies. [2,3]. The incidence of
twin pregnancies remains high due to an increase in the
age of pregnant women. Prevention of preterm birth is
therefore a major goal of obstetric care. However, strate-
gies to prevent preterm birth have been largely unsuccess-
ful.
Bad neonatal outcome includes respiratory distress syn-
drome (RDS), bronchopulmonary dysplasia (BPD), intra-
ventricular haemorrhage (IVH), periventricular
leucomalacia (PVL), necrotizing enterocolitis (NEC), sep-
sis and death before discharge [4]. The prevalence of this
poor neonatal outcome is 77%, 35% and 12% in children
born after early preterm delivery between 24-27, 28-32
and 32-34 weeks, respectively [3]. But after 34 weeks this
incidence sharply declines to less than 2% at term. The
probability that a woman with a multiple pregnancy
delivers at these gestational ages is 1.8%, 5.4% and 7.2%,
respectively [2].
In total, about 8% of the multiple pregnancies will result
in the death of at least one child, whereas in 7% of the
pregnancies at least one of the children will remain
severely disabled. Moreover, another 20% of the pregnan-
cies results in a moderate handicap of at least one of the
children.
The cost of these poor outcome is enormous. About 500
of these children will be admitted into a neonatal inten-
sive care unit at a cost of n 1500,- per day, with an average
duration of admission of 10 days. This results in a total
cost of 16 million euro per year from the birth of 1.000
children before 34 weeks.
A pessary is a simple and potentially effective measure for
the prevention of preterm birth.
Preliminary evidence on the effectiveness of a pessary to
prevent preterm labour is promising. Various designs of
pessary have been used[5] but none has been evaluated in
a well-designed randomised trial. In the only randomised
controlled trial of pessary prophylaxis comparing pessary
to cerclage [6], the type of pessary used and the study
methodology were not well described. A double ring
shaped pessary is at present the most popular pessary, and
widely used in The Netherlands and Germany with the
manufacturers selling around 2000 per year.
The first reports show a strong beneficial effect of a pessary
in women with singleton pregnancies and a short cervix
[7]. A cohort study in twins showed that a pessary pro-
longed pregnancy and decreased delivery before 32 weeks
[8]. A prospective cohort study by Acharya et al. also used
an double ring shaped pessary (Arabin-pessary) to treat
cervical incompetence in women with a cervical length 
25 mm, before 30 weeks [9]. This study showed that in 55
percent of the patients, the pregnancy could be postponed
to 34 weeks or more. In view of these data, we will set up
a randomised clinical trial on the subject. The aim of this
trial is to investigate whether a prophylactic cervical pes-
sary will lower the incidence of neonatal morbidity by
reducing the number of preterm births in multiple preg-
nancy.
Methods/Design
Aims
We will use a randomised trial (the ProTwin-trial: Pessa-
ries in multiple pregnancy as a prevention of preterm
birth: the ProTwin Trial) to assess the effect of a cervical
pessary on neonatal outcome.
The study is set in the Dutch Obstetric Research Consor-
tium, a collaboration of obstetric practices in the Nether-
lands. Approximately 50 clinics, including academic
hospitals, non-academic teaching hospitals and non-
teaching hospitals will participate in this trial.Page 2 of 5
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Ethics Committee, Academic Medical Centre, Amsterdam,
The Netherlands (MEC O9/1O7).
Participants
All women presenting with a multiple pregnancy between
12 and 19 weeks of gestation are eligible for the study. We
propose to also include women with monochorionic
pregnancies as well as women with a triplet pregnancy or
women with a previous preterm birth. Women with mul-
tiple pregnancies in which at least one of the foetuses has
major congenital anomalies known at study entry will not
be included. Gestational age will be determined from the
menstrual history and confirmed from the measurement
of foetal crown-rump length (of the bigger twin) at a first-
trimester scan.
Procedures, recruitment, randomisation and collection of 
baseline data
All eligible women who present at one of the participating
clinics will be referred to an obstetrician or a specifically
appointed research nurse/midwife for counselling. They
will receive an information sheet and, where possible, are
given two weeks time to reflect on participation.
Once a patient has given informed consent, and the
patient data have been entered in a web-based database,
randomisation will be done over the internet.
Randomisation will be stratified for centre, parity (previ-
ous vaginal delivery or not), chorionicity (multichorial
versus monochorial) and number of multiples (twin or
higher order gestation).
We will apply block randomisation with a variable block
size and a minimalisation procedure. The pessaries will be
packaged according to the randomisation sequence at the
central consortium office in Amsterdam, the Netherlands.
Randomisation will be 1:1 for cervical pessary versus no
treatment.
The study will not be blinded.
Baseline demographic, past obstetric and medical histo-
ries will be recorded for all women. Cervical length will be
measured by transvaginal ultrasound at the time of ran-
domisation or at the next visit.
Intervention
Eligible women will be randomly allocated to receive
either a cervical pessary (Arabin pessary) or no interven-
tion. The cervical pessary will be placed in situ at 16 to 20
weeks, and will stay in situ up to 36 weeks gestation or
until delivery, whatever comes first.
All women participating will have a transvaginal measure-
ment for cervical length between a gestational age of 18 to
22 weeks. Next to this research intervention cases are
treated according to the local protocol in the participating
clinics and other interventions i.e. tocolysis and corticos-
teroids in case of a threatened preterm birth can be carried
out as usual. Furthermore no extra interventions will be
needed. The use of progesterone is allowed, but this will
mainly depend on the outcome of our current AMPHIA
study[10].
Outcome measures
The main outcome parameter is the composite morbidity
rate of children in the two groups. This composite mor-
bidity rate contains the following variables: periventricu-
lar leukomalacia (PVL), severe Respiratory Distress
Syndrome (RDS), Broncho Pulmonal Dysplasia (BPD),
Intraventricular Haemorrhage II B or worse, Necrotizing
Enterocolitis (NEC), proven sepsis and death before dis-
charge from the nursery 24. They will be measured until 6
weeks after the expected term date of delivery.
Secondary outcome measures are time to delivery, pre-
term birth rate before 32 and 37 weeks, days of admission
in neonatal intensive care unit, maternal morbidity,
maternal admission days for preterm labour and costs. At
present, a longer follow-up is not planned.
Follow up of women and infants
All details of delivery, maternal assessments and admit-
tance during pregnancy are recorded in the case record
form that is accessible through the website. In case of
admittance of one or more children to the neonatal inten-
sive care unit, details of this admittance are also recorded.
The main outcome parameter, a composite neonatal mor-
tality and morbidity, will be measured until 6 weeks after
the expected term date of delivery.
Long-term follow up of children is desirable, but is
depending on future funding
Economic evaluation
General considerations
The economic evaluation will be performed from a soci-
etal perspective, with the costs per unit reduction in the
primary outcome ('bad neonatal outcomes') as the pri-
mary outcome measure. The appropriate type of eco-
nomic evaluation is conditional on the results. We
hypothesize that when a pessary is effective, this interven-
tion will be associated with less neonatal health care utili-
zation, as well as less burden to parents (time costs) and
absence from paid work (productivity costs). Therefore,
the primary analysis will be a cost-effectiveness analysis
that evaluates costs associated with an improved neonatal
outcome, expecting the peccary intervention to be domi-Page 3 of 5
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of 12 months after delivery, no discounting will be
applied. Study specific costs will be excluded from the
analyses.
Cost analysis
We will differentiate between direct medical, direct non-
medical and indirect costs. Within direct medical costs,
the process of care is distinguished into three stages: ante-
natal stage, delivery/childbirth and postnatal stage. In the
antenatal stage, costs are generated by health care utiliza-
tion related to the placement and check of the peccary,
hospital care and outpatient visits. Costs during childbirth
are dominated by the course of childbirth and type of
delivery. In the postnatal stage, costs are generated by hos-
pital-based maternal care (hospitalisation etc.), neonatal
care (admission to NICU/medium care or maternity ward,
related diagnostic care and treatment, outpatient visits),
primary care and informal care.
If neonatal health is suboptimal, further direct medical,
direct non-medical and indirect costs may occur. Hence,
for these infants, resource use of infants and/or parents is
measured during 12 months after childbirth. Direct non-
medical costs in the antenatal and postnatal stages are
generated by travel to and from health care providers, and
time costs as the result of household shifts. Indirect costs
are associated with lost productivity due to absence from
paid work, predominantly in the postnatal stage.
Statistical issues
Sample size
The sample size is calculated based on the primary out-
come 'bad neonatal outcome'. In the control group, 'bad
neonatal outcome' is expected in 7.2% of the children
(1.8%*77% + 5.4%*35% + 7.2%*12% + 35.6%*8% +
50%*.5% = 7.2%). In this calculation, the first rate repre-
sents the probability that a patient delivers at that gesta-
tional age, whereas the second rate represents the
probability of 'bad neonatal outcome' at that particular
gestational age. In case of treatment, 'bad neonatal out-
come' is then expected in 3.9% of the children
(0.9%*77% + 2.7%*35% + 3.6%*12% + 17.8%*8% +
75%*.5% = 3.9%).
Because the outcomes in children from multiple pregnan-
cies are to a certain extent non-independent, we adjusted
our sample size assuming a correlation of 0.6 for compos-
ite neonatal morbidity between two children born from
the same pregnancy[11]. Using a two-sided test with an
alpha of 0.05 and a power of 0.80 we need 330 women in
the control group and 330 in the intervention group (total
of 660 women).
Data analysis
Data will initially be analysed according the intention to
treat method. The main outcome variable, 'bad neonatal
outcome', will be assessed by calculating rates in the two
groups, relative risks and 95% confidence intervals as well
as numbers needed to treat. To evaluate the potential of
each of the strategies, we will also perform a par protocol
analysis, taking into account only those cases that were
treated according to protocol.
Time to delivery will be evaluated by Kaplan-Meier esti-
mates, with account for differing durations of gestation at
entry, and will be tested with the logrank test. The other
secondary outcome measures will be approached simi-
larly to the primary outcome measure.
We plan a separate analysis of women with a cervical
length below 25 mm at 18 tot 22 weeks, and we will look
at interaction between cervical length and treatment
effect.
Interim analysis
An interim analysis will be performed after the inclusion
of 300 women. This analysis will be done by an independ-
ent data and safety monitoring committee that will not be
aware of the allocation of pessary or no treatment when
they judge data on effectiveness. In case of severe side-
effects, the safety monitoring committee can advise to
stop the study.
Discussion
In the past, a lot of strategies have been used to prevent
preterm birth in singleton and multiple pregnancies, like
bed rest, uterine activity monitoring, prophylactic tocoly-
sis and primary cerclage. However, none of these strate-
gies have been proven to be effective.
A pessary is a simple and potentially effective measure for
the prevention of preterm birth. Small studies have indi-
cated its effectiveness, but large studies with sufficient
power on the subject are lacking. Despite this lack of evi-
dence, the treatment is at present applied by some gynae-
cologists in The Netherlands. From that perspective, and
taking into account the major medical and social implica-
tions of preterm birth, research has to be done into the
possible beneficial effects of progesterone in multiple
pregnancies
Simultaneously with the ProTwin-trial, a number of other
study groups in different countries have set up trials to
investigate the effectiveness of a cervical pessary in pre-
venting preterm birth in singleton as well as in multiple
pregnancies. There is a trial in Spain [7], one in France
[12] and one in the United Kingdom [13]. This last study
will include patients in Brazil, Chile, Colombia, Germany,Page 4 of 5
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India, Portugal, Spain and the United Kingdom. If the out-
come data of these studies are pooled, a more conclusive
statement can be made on this matter.
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